

Experiment title:	Experiment
Structural bases of activation of cyclin-dependent kinase 5	number:
(Cdk5).	LS1933

<u>ESKF</u>	(Cala).	L31933
Beamline:	Date of experiment:	Date of report:
ID14-3	from 28-04-2001 to 30-04-2001	25-07-01
ID29	from 23-06-2001 to 25-06-2001	
Shifts to BAG:	Local contact(s):	Received at ESRF:
12	Edward Mitchell	
6	Andy Thompson	

Names and affiliations of applicants (* indicates experimentalists):

(*) Andrea Musacchio, Cataldo Tarricone, Lucia Sironi

Department of Experimental Oncology

European Institute of Oncology

Via Ripamonti 435

20141 Milan

Italy

Cyclin-dependent kinases (CDKs) constitute a family of serine/threonine kinases whose activity is regulated by the

interaction with proteins known as cyclins (Morgan, 1995). Although most CDKs have been implicated in the regulation

of the cell division cycle, emerging evidence indicates that certain members of this family are involved in other

processes. An important example is represented by CDK5, whose function is critical during neuronal development

(Smith et al., 2001). CDK5 substrates include the neuron-specific cytoskeletal proteins Neurofilament and Tau, the

LIS1 and Dynein associated protein Nudel, the synaptic protein Synapsin 1 and the Munc18/Syntaxin1A complex.

CDK5 has also been shown to phosphorylate proteins involved in functions of the mature brain. CDK5 phosphorylates

DARPP32, a neuronal striatum specific protein regulating dopamine signaling, rendering it an inhibitor of PKA.

Phosphorylation of DARPP32 by CDK5 was further shown to dampen the effect of chronic cocaine treatment

indicating a possible regulatory role of CDK5 in drug addiction.

Deregulation of CDK5 activity upon conversion of p35 to p25 has been implicated in neurodegenerative diseases. p25 is

a 208 residue C-terminal proteolytic product of p35. The accumulation of p25 in human brain tissues correlates with AD

affection. Conversion of p35 to p25 by calpain can be induced by a variety of neurotoxic conditions including ischemia,

excitotoxicty, and beta amyloid peptide. Despite the fact that both p35 and p25 efficiently activate CDK5, p25 displays

distinct properties from p35. First, p35 is a very unstable protein with a half-life of 20 to 30 minutes while p25 displays a

substantially longer half-life. In addition, p35 localizes to cellular membranes by virtue of an N-terminal myristoylation

motif. In neurons, p35 is present throughout the entire cell including the tips of processes. p25 lacks the myristoylation

site and is concentrated in the cell body and nucleus in neurons. These properties of p25 lead to deregulation of CDK5

kinase activity in vivo, which is associated with tau hyper-phosphorylation, cytoskeletal disruptions, and apoptotic death

of neurons. Thus, conversion of p35 to p25 may play a role in the pathogenesis of AD.

Recently, we have determined the structure of the CDK5-p25 complex (Tarricone et al., In the press). We are now

concentrating on the possibility of collecting co-crystals of CDK5 with kinase inhibitors. This effort may improve our

understanding of the structural bases of selective CDK inhibition, and might contribute to the discovery of drugs to fight

AD. Crystals of CDK5/p25 are relatively poor diffractors, are brittle, and tend to grow as twinned plates. During our

experiments in Grenoble we were able to collect a single high-quality data set from crystals soaked in different CDK

inhibitors. In particular, we were able to collect a dataset from a crystal soaked in Indirubin. Compared with other

previously collected datasets, this is of particularly high quality, and of considerably higher resolution that those

previously available. The structure is being refined, and indirubin is clearly visible in the electron density (Tarricone et

al. In preparation).

References

Morgan, D. O. (1995). Principles of CDK regulation. Nature 374, 131-4.

Table: Summary of CDK5/p25 data collection (ID14-3, 28-04-01 to 30-04-01)

Crystal complex with indirubin

Space Group P21

Unit cell $a=87.3 \text{ b}= 142.7 \text{ Å, c}=82.5 \text{ Å, beta}=94.2^{\circ}$

Resolution 2.3 Å

 N° measurements 160456

N° reflections 51760

Completeness 98.8 %

Rsym 7.5 %

Postal address: User Office, ESRF, B.P. 220, F-38043 GRENOBLE Cedex, France Street address: 6 rue Jules Horowitz, F-38043 GRENOBLE Cedex Telephone: +33 (0)4 7688 2552; Fax: +33 (0)4 7688 2020; e-mail: useroff@esrf.fr